Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant
Status:
Unknown status
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, interventional, case-control study at King Faisal Specialist Hospital
& Research Centre in post-renal transplant patients who are receiving Grazoprevir/Elbasvir
combination. Data will be compared with matched historical controls, which will be selected
according to the following matching criteria: age, time from transplant to initiation of
therapy. Only patients who completed at least 48 weeks of pegylated Interferon + Ribavirin
therapy in the control group and 12 weeks of therapy on the case group will be enrolled. Any
patient who received at least one dose of Grazoprevir/Elbasvir combination will be included
in the safety analysis.